Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2021-08-01 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Lapse of performance rights 1 page 185.1KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (812 characters) notifying the market about the lapse of employee performance rights under a specific employee plan. It does not contain financial statements, detailed financial data, or management discussion. It is an update related to share-based compensation but does not report on financial results or governance changes. It is not a full report but a regulatory announcement about share rights. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-01 English
NEXTSTELLIS oral contraceptive now available in the US 3 pages 127.9KB
Regulatory Filings Classification · 95% confidence The document is a joint press release announcing the commercial launch of a new oral contraceptive product, NEXTSTELLIS, in the United States. It contains promotional and product information, quotes from CEOs, market context, and contact details for investor relations and press. There are no financial statements, regulatory filings, voting results, or management discussions of financial results. The content is typical of a press release announcing a product launch rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The best fitting category is a general Regulatory Filings (RNS) as a press release announcement that does not fit other specific categories.
2021-06-20 English
Mayne Pharma expands Australian dermatology portfolio 2 pages 158.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 21 June 2021 from Mayne Pharma Group Limited about licensing and expanding its Australian dermatology product portfolio. It discusses product acquisitions, regulatory approvals, market information, and future plans. There are no financial statements, quarterly or annual results, nor any detailed financial data or management discussion of financial performance. The document is a corporate announcement about business development activities and product licensing, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. Therefore, the document fits best into the category of Capital/Financing Update (CAP) as it relates to licensing and portfolio expansion, which is a form of business and capital activity update.
2021-06-20 English
NEXTSTELLIS FDA exclusivity & phase III data published 3 pages 220.3KB
Capital/Financing Update Classification · 90% confidence The document is a joint press release announcing that the drug NEXTSTELLIS has received FDA marketing exclusivity and that Phase III clinical trial data has been published in a peer-reviewed journal. It contains detailed clinical trial results, safety and efficacy data, and statements from company executives. The document is not a financial report, regulatory filing, or management discussion. It is a corporate announcement focused on product development and clinical trial outcomes. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is consistent with a Capital/Financing Update (CAP) because it announces a significant regulatory milestone (FDA exclusivity) and clinical data publication, which are material events relevant to investors and the market. Therefore, the best classification is Capital/Financing Update (CAP).
2021-05-26 English
Becoming a substantial holder 17 pages 1.2MB
Regulatory Filings
2021-05-13 English
Appendix 2A and Notice under ASX Listing Rule 3.10A 16 pages 881.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Mayne Pharma Group Limited regarding the issuance of new shares and a notice under ASX Listing Rule 3.10A. It includes details about the number of shares issued, the recipient, and the escrow period. The document also contains an Appendix 2A, which is a standard form used for the application for quotation of securities on the ASX. The content focuses on share issuance and capital changes rather than financial results, management changes, or other report types. The presence of the Appendix 2A and the nature of the announcement clearly indicate this is a Share Issue/Capital Change filing. The document length and detail confirm it is not a mere announcement of a report but the actual filing of the share issue information.
2021-05-12 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.